🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting over 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

According to findings published in a prominent scientific publication, zoliflodacin cured over nine in ten of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves two antibiotics. The trial involved nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced optimism. Access to a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea globally.